Cargando…

Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial

Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex, renal angiomyolipoma and tuberous sclerosis complex, and, in c...

Descripción completa

Detalles Bibliográficos
Autor principal:	Peterson, Mary E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699701/ https://www.ncbi.nlm.nih.gov/pubmed/23686401 http://dx.doi.org/10.1007/s00520-013-1826-3

Ejemplares similares

Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
por: Yi, Zongbi, et al.
Publicado: (2017)

Statin use in patients with hormone receptor‐positive metastatic breast cancer treated with everolimus and exemestane
por: Lee, Kyoungmin, et al.
Publicado: (2022)

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
por: Rugo, H. S., et al.
Publicado: (2014)

Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus
por: Peddi, Parvin F., et al.
Publicado: (2020)

RETRACTION: Challenges of Combined Everolimus/Endocrine Therapy in Hormone Receptor-Positive Metastatic Breast Cancer
por: Porta, Camillo
Publicado: (2014)

Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report
por: Ballatore, Z., et al.
Publicado: (2016)

Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study
por: François-Martin, Hélène, et al.
Publicado: (2023)

Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib
por: Dhakal, Ajay, et al.
Publicado: (2020)

Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor‐Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care‐BC): A Randomized Controlled Phase III Trial
por: Niikura, Naoki, et al.
Publicado: (2019)

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer
por: Vaklavas, Christos, et al.
Publicado: (2023)

Adverse Events of Everolimus in Patients with Tuberous Sclerosis Complex Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma
por: Gau, Shuo-Yan, et al.
Publicado: (2023)

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
por: Rozenblit, Mariya, et al.
Publicado: (2021)

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
por: Schmid, Peter, et al.
Publicado: (2023)

New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
por: Paplomata, Elisavet, et al.
Publicado: (2013)

Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide
por: Davies, Mark, et al.
Publicado: (2017)

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
por: Noguchi, Shinzaburo, et al.
Publicado: (2013)

Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
por: Schettini, Francesco, et al.
Publicado: (2020)

Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
por: Sirico, Marianna, et al.
Publicado: (2020)

Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
por: Raphael, Ari, et al.
Publicado: (2022)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
por: Schmid, Peter, et al.
Publicado: (2021)

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial
por: Hadji, Peyman, et al.
Publicado: (2018)

Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
por: Nakatsukasa, Katsuhiko, et al.
Publicado: (2021)

A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Metastases
por: Beck, J. Thaddeus, et al.
Publicado: (2015)

Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta-analysis
por: Yamanaka, Kenya, et al.
Publicado: (2013)

Treating Elderly Patients With Hormone Receptor–Positive Advanced Breast Cancer
por: Riseberg, David
Publicado: (2015)

Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Zhang, Hui-Qiang, et al.
Publicado: (2021)

Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study
por: Kourlaba, Georgia, et al.
Publicado: (2015)

Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus
por: Arora, Shalabh, et al.
Publicado: (2016)

Adverse Events in Treating Smear-Positive Tuberculosis Patients in China
por: Zhang, Tao, et al.
Publicado: (2015)

Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan
por: Kikawa, Yuichiro, et al.
Publicado: (2019)

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
por: Yi, Zongbi, et al.
Publicado: (2019)

E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
por: Yeruva, Sri Lakshmi Hyndavi, et al.
Publicado: (2018)

Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review
por: Komorowski, Adam S., et al.
Publicado: (2020)

Effect of Adjunct Balloon Dilation after Long Everolimus-eluting Stent Deployment on Major Adverse Cardiac Events
por: Hong, Sung-Jin, et al.
Publicado: (2017)

Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
por: Altalib, Hamada, et al.
Publicado: (2022)

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trial
por: Tesch, Hans, et al.
Publicado: (2018)

Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
por: James, Elizabeth C., et al.
Publicado: (2020)

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
por: Rugo, Hope S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l6fl9uv245dn63f31gio4ojs7l